Mode
Text Size
Log in / Sign up
N/A N=293

Current Adoption of Composite Indices in Evaluating Rheumatoid Arthritis Patients: An Observational Study

Rheumatoid Arthritis

Enrolled (actual)
293
Serious AEs
1.4%
Results posted
Feb 2013
Primary outcome: Primary: Percentage of Participants With Remission as Per Modified American College of Rheumatology (Modified ACR) Criteria at Month 6

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
As per routinary clinical care (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Pfizer
Primary completion
Jun 2010

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants With Remission as Per Modified American College of Rheumatology (Modified ACR) Criteria at Month 6
PRIMARY
Percentage of Participants With Remission as Per Modified American College of Rheumatology (Modified ACR) Criteria at Month 12
PRIMARY
Minimal Disease Activity: Outcome Measures in Rheumatology Arthritis Clinical Trials (OMERACT) at Month 6
PRIMARY
Minimal Disease Activity: Outcome Measures in Rheumatology Arthritis Clinical Trials (OMERACT) at Month 12
PRIMARY
Minimal Disease Activity: Italian Group for the Study of Early Arthritis (GISEA) at Month 6
PRIMARY
Minimal Disease Activity: Italian Group for the Study of Early Arthritis (GISEA) at Month 12
PRIMARY
Number of Swollen Joints (SJC) and Tender Joints (TJC) at Month 6
2.80; 4.62
PRIMARY
Number of Swollen Joints (SJC) and Tender Joints (TJC) at Month 12
1.28; 2.35
PRIMARY
Disease Activity Score Based on 28-joints Count (DAS28) at Month 6
PRIMARY
Disease Activity Score Based on 28-joints Count (DAS28) at Month 12
PRIMARY
Simplified Disease Activity Index (SDAI) at Month 6
PRIMARY
Simplified Disease Activity Index (SDAI) at Month 12
PRIMARY
Rheumatoid Arthritis Disease Activity Index (RADAI) at Month 6
3.26
PRIMARY
Rheumatoid Arthritis Disease Activity Index (RADAI) at Month 12
2.83
PRIMARY
Clinical Disease Activity Index (CDAI) at Month 6
PRIMARY
Clinical Disease Activity Index (CDAI) at Month 12
PRIMARY
Patient Reported Outcomes - Clinical Arthritis Activity (PRO-CLARA ) at Month 6
PRIMARY
Patient Reported Outcomes - Clinical Arthritis Activity (PRO-CLARA ) at Month 12
PRIMARY
Clinical Arthritis Activity (CLARA) Index at Month 6
1.79
PRIMARY
Clinical Arthritis Activity (CLARA) Index at Month 12
1.39
PRIMARY
Patient Global Assessment (PtGA) of Disease Activity at Month 6
3.71
PRIMARY
Patient Global Assessment (PtGA) of Disease Activity at Month 12
3.35
PRIMARY
Physician Global Assessment (PGA) of Disease Activity at Month 6
3.11
PRIMARY
Physician Global Assessment (PGA) of Disease Activity at Month 12
2.60
PRIMARY
Visual Analog Fatigue Scale (VAFS) at Month 6
PRIMARY
Visual Analog Fatigue Scale (VAFS) at Month 12
PRIMARY
C-reactive Protein (CRP) at Month 6
2.16
PRIMARY
C-reactive Protein (CRP) at Month 12
1.63
PRIMARY
Erythrocyte Sedimentation Rate (ESR) at Month 6
26.02
PRIMARY
Erythrocyte Sedimentation Rate (ESR) at Month 12
21.92
PRIMARY
Number of Participants With Rheumatoid Factor (RF) at Month 6
PRIMARY
Number of Participants With Rheumatoid Factor (RF) at Month 12
PRIMARY
Patient's General Health Assessment at Month 6
PRIMARY
Patient's General Health Assessment at Month 12
PRIMARY
Patient Assessment of Arthritis Pain at Month 6
3.58
PRIMARY
Patient Assessment of Arthritis Pain at Month 12
3.29
PRIMARY
Duration of Morning Stiffness at Month 6
PRIMARY
Duration of Morning Stiffness at Month 12
PRIMARY
Health Assessment Questionnaire (HAQ) at Month 6
0.83
PRIMARY
Health Assessment Questionnaire (HAQ) at Month 12
0.68
PRIMARY
Recent-Onset Arthritis Disability (ROAD) at Month 6
2.28
PRIMARY
Recent-Onset Arthritis Disability (ROAD) at Month 12
1.97
PRIMARY
Radiological Assessment of Hands and Feet Based on Sharp-van Der Hejde (SvH) Scoring Method at Month 6
PRIMARY
Radiological Assessment of Hands and Feet Based on Sharp-Van Der Hejde (SvH) Scoring Method at Month 12

Summary

This is an observational study of composite indices, including the CLARA (CLinical ARthritis Activity) index, in rheumatoid arthritis (RA) patients in routine clinical practice in Italy in order to evaluate clinical remission and low disease activity. Data will be collected only from patients providing informed consent. In this study we aimed to assess the psychometric properties of a new composite instrument termed CLinical ARthritis Activity (PRO-CLARA) that uses only three PRO measures from among the 7 ACR Core Data Set. We hypothesized that this index would facilitate rapid and easy RA activity assessment in daily routine.

Eligibility Criteria

Inclusion Criteria

  • Eighteen years of age or older with diagnosis of RA based on the 1987 American College of Rheumatology (ACR) criteria and in accordance with local guidelines.
  • Patients eligible to anti-TNF therapy
  • Patients naïve to anti-TNFa drugs
  • Patients with radiography (hands and feet) executed by 6 months before the baseline or at baseline according to modified Sharp Van der Hejde method [Sharp JT et al. 1985; Sharp JT. Et al. 1989; Van der Heijde DM et al. 1989] Patients capable of understanding and completing the questionnaire Patients capable of understanding and signing an informed consent form

Exclusion Criteria

  • Patients with tumors
  • Patients already included in clinical trials
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00793403). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search